04_07 Localized Renal Cell Carcinoma

1. RAS as an oncogene 2. The undruggable RAS 3. KRAS G12C as a specific exception 4. Daroxonrasib as a pan RAS(On) inhibitor Citations As always, citations, and sources include education from our re...

8 Kesä 14min

1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education...

3 Touko 202527min

1. Etiologies and epidemiology 2. Staging and local/regional considerations 3. Systemic Therapy 4. Differences in immune checkpoint sensitivity by etiology Citations As always, citations, and sources ...

19 Joulu 202432min

1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective trainin...

27 Loka 202425min

1. Background, work up 2. Staging of seminoma and NSGCT 3. Young Adult/Adolescent Oncology 4. Management of Stage I Disease Citations As always, citations, and sources include education from our res...

18 Syys 202428min

1. Historical Approach (cytoreduction, IFN-a, sunitinib 2. Prognostic risk scores 3. Evidence for modern doublet regimens 4. Later line therapy Citations As always, citations, and sources include educ...

2 Elo 202424min

1. Immunohistochemistry of urothelial cancer 2. History of systemic therapy in advanced and metastatic disease 3. Pembrolizumab and Enfortumab Vedotin 4. Approach to second line therapy and beyond Cit...

24 Touko 202424min